Resiquimod (R-848)

Catalog No.S8133 Synonyms: S28463

For research use only.

Resiquimod (R-848, S28463) is an immune response modifier that acts as a potent TLR 7/TLR 8 agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α. Resiquimod reduces hepatitis C virus (HCV) infection. Phase 2.

Resiquimod (R-848) Chemical Structure

CAS No. 144875-48-9

Selleck's Resiquimod (R-848) has been cited by 10 Publications

Purity & Quality Control

Choose Selective TLR Inhibitors

Biological Activity

Description Resiquimod (R-848, S28463) is an immune response modifier that acts as a potent TLR 7/TLR 8 agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α. Resiquimod reduces hepatitis C virus (HCV) infection. Phase 2.
Targets
TLR7 [1] TLR8 [1]
In vitro

Resiquimod activates immune cells and induces proliferation of wild-type splenocytes via the Toll-like receptor 7 (TLR7)-MyD88-dependent signaling pathway. [1] Resiquimod also modulates dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses. [2] Resiquimod induces the differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells, and may improve cancer immunotherapy by reducing immunosuppressive MDSCs. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PBMC MYDGeY5kfGmxbjDhd5NigQ>? NEH0OoI{OCCwTR?= M1TiPFE5KGi{cx?= MoDMTY5lfWO2aX;uJI9nKHS7cHWgNUBKTk5ic3XjdoV1cW:wIHnuJIh2dWGwIGDCUWMh[XRiM{Cgcm0h[W[2ZYKgNVghcHK|IHL5JGVNUVODLDDBZ5Rqfmm2eU2wMlAxOTJ3zszNMi=> NXOzdpdkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCyN|I5OjRpPkKwNlMzQDJ2PD;hQi=>
PBMC NE\aZYNHfW6ldHnvckBie3OjeR?= MkPMNVAhdk1? M1[4PFE5KGi{cx?= NHLJT|lKdmS3Y4Tpc44hd2ZidInw[UAyKEmITjDz[YNz\XSrb36gbY4hcHWvYX6gVGJOSyCjdDCxNEBvVSCjZoTldkAyQCCqcoOgZpkhTUyLU1GsJGFkfGm4aYT5QFAvODBzMkZOwG0v NWjXbWYxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCyN|I5OjRpPkKwNlMzQDJ2PD;hQi=>
PBMC NU\QS5M2TnWwY4Tpc44h[XO|YYm= MkHXNVAxKG6P NXrDUm04OThiaILz MkLLTY5lfWO2aX;uJI9nKHS7cHWgNUBKTk5ic3XjdoV1cW:wIHnuJIh2dWGwIGDCUWMh[XRiMUCwJI5OKGGodHXyJFE5KGi{czDifUBGVEmVQTygRYN1cX[rdIm9NE4xODV4Md88UU4> MlTCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB{M{K4NlQoRjJyMkOyPFI1RC:jPh?=
PBMC MYDGeY5kfGmxbjDhd5NigQ>? MVuzNFAhdk1? NG\k[2wyQCCqcoO= NG\qXGFKdmS3Y4Tpc44hd2ZidInw[UAyKEmITjDz[YNz\XSrb36gbY4hcHWvYX6gVGJOSyCjdDCzNFAhdk1iYX\0[ZIhOThiaILzJIJ6KEWOSWPBMEBC[3Srdnn0fV0xNjByN{K2{txONg>? NHzWWW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEKzNlgzPCd-MkCyN|I5OjR:L3G+
PBMC MUnGeY5kfGmxbjDhd5NigQ>? MXWxNFAxKG6P MXmxPEBpenN? M4jaUGlv\HWldHnvckBw\iC2eYDlJFEhUU[QIIPlZ5JmfGmxbjDpckBpfW2jbjDQRm1EKGG2IEGwNFAhdk1iYX\0[ZIhOThiaILzJIJ6KEWOSWPBMEBC[3Srdnn0fV0xNjByN{e1{txONg>? NE\NUmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEKzNlgzPCd-MkCyN|I5OjR:L3G+
Huh7 NFfnUldCdnSrdnnyZYwh[XO|YYm= M1TpT|Q5KGi{cx?= MnLzRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGNXKGmwZnXjeIVlKGi3bXHuJGh2cDdicnXwcIlkd25iY3XscJMhfHKnYYTl[EBnd3JiNEigbJJ{KHerdHig[JJ2\y2rbnT1Z4VlKG2reHXkJIRwdm:{IHj1cYFvKFCETVOgd5Vx\XKwYYThcpR{KGG|c3Xzd4VlKGG|II\pdoFtKGyndnXsd{BjgSCudXPp[oVz[XOnIHHzd4F6NCCHQ{WwQVAvODJ2zszNMi=> MmW3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3NEi0PVcoRjF5NUS4OFk4RC:jPh?=
Huh7 M2S2[GFvfGm4aYLhcEBie3OjeR?= NIT2[Zk1QCCqcoO= NVPrXIFxSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEOYIHnu[oVkfGWmIHj1cYFvKEi3aEegdoVxdGmlb36gZ4VtdHNidILlZZRm\CCob4KgOFghcHK|IIfpeIgh\HK3Zz3pcoR2[2WmIIPpcodt\SCmb37vdkBpfW2jbjDQRm1EKHO3cHXycoF1[W62czDhd5Nme3OnZDDhd{B3cXKjbDDs[ZZmdHNiYomgcJVkcW[ncnHz[UBie3OjeTygSWM2OD1yLkCyOlXPxE1w MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV2OES5O{c,OTd3NEi0PVc9N2F-
PBMC MYjGeY5kfGmxbjDhd5NigQ>? MXOyOEBpenN? Mlu4TY5lfWO2aX;uJI9nKEmITnHsdIhiOmFibHX2[YwhcW5iaIXtZY4hWEKPQzDhd5Nme3OnZDDhd{BlenWpIHzleoVtKGOjdYPpcochdWG6aX3hcEBkgXSxa3nu[UBqdmS3Y4Tpc44h[W[2ZYKgNlQhcHK|IILlcIF1cX[nIITvJINwdnS{b3ysJGFkfGm4aYT5QVAvOc7:TT6= M2rwRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUS4OFk4Lz5zN{W0PFQ6PzxxYU6=
PBMC MWXGeY5kfGmxbjDhd5NigQ>? MonRNlQhcHK| M3P5NHRwgGmlIHnu[JVkfGmxbjDv[kBKVDFvYnX0ZUBt\X[nbDDpckBpfW2jbjDQRm1EKGG|c3Xzd4VlKGG|IHTyeYchdGW4ZXygZ4F2e2mwZzDtZZhqdWGuIHP5eI9scW6nIHnu[JVkfGmxbjDh[pRmeiB{NDDodpMhemWuYYTpeoUhfG9iY3;ueJJwdCxiQXP0bZZqfHl;Md88UU4> MoXzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3NEi0PVcoRjF5NUS4OFk4RC:jPh?=
PBMC NX7PbXJQTnWwY4Tpc44h[XO|YYm= MoDUNlQhcHK| NV3vcnBDXG:6aXOgbY5lfWO2aX;uJI9nKEmONjDs[ZZmdCCrbjDoeY1idiCSQl3DJIF{e2W|c3XkJIF{KGS{dXegcIV3\WxiY3H1d4lv\yCvYYjpcYFtKGO7dH;rbY5mKGmwZIXjeIlwdiCjZoTldkAzPCCqcoOgdoVt[XSrdnWgeI8h[2:wdILvcEwhSWO2aY\peJk:Oc7:TT6= NISxWmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W0PFQ6Pyd-MUe1OFg1QTd:L3G+
PBMC NH\DNohHfW6ldHnvckBie3OjeR?= M3T2OVI1KGi{cx?= NWfUVmx7XG:6aXOgbY5lfWO2aX;uJI9nKFSQRnHsdIhiKGyndnXsJIlvKGi3bXHuJHBDVUNiYYPz[ZN{\WRiYYOg[JJ2\yCuZY\lcEBk[XW|aX7nJI1igGmvYXygZ5l1d2urbnWgbY5lfWO2aX;uJIFnfGW{IEK0JIhzeyC{ZXzheIl3\SC2bzDjc451em:uLDDBZ5Rqfmm2eU2x{txONg>? MoWxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3NEi0PVcoRjF5NUS4OFk4RC:jPh?=
HEK293 M2WxfmZ2dmO2aX;uJIF{e2G7 M1TNNlYhcHK| M4jjbGFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gWGxTPyCneIDy[ZN{\WRiaX6gTGVMOjl|IHPlcIx{KGGodHXyJFYhcHK|IHL5JG5Hc2GycHHCMYx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiTVXDQVAvOc7:TT6= MnjkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzBzNEO0NlUoRjNyMUSzOFI2RC:jPh?=
HEK293 MXPGeY5kfGmxbjDhd5NigQ>? M3nJR2Fod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gWGxTPyCneIDy[ZN{\WRiaX6gTGVMOjl|IHPlcIx{KGOxZYjwdoV{e2mwZzDwUolHfHl{LWPFRXAhemWyb4L0[ZIh[nlicnXwc5J1\XJiZ3Xu[UBie3OjeTygSWM2OD1yLkK2NFHPxE1w M3Xvd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMkOyPFI1Lz5{MEKzNlgzPDxxYU6=
HEK293 MmLBSpVv[3Srb36gZZN{[Xl? M{K3b|YhcHK| M33BcWFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gWGxTQCCneIDy[ZN{\WRiaX6gTGVMOjl|IHPlcIx{KGGodHXyJFYhcHK|IHL5JG5Hc2GycHHCMYx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiTVXDQVAvO87:TT6= M4nw[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMUSzOFI2Lz5|MEG0N|QzPTxxYU6=
HEK M1P6dWZ2dmO2aX;uJIF{e2G7 NV7Q[ZNUQCC2bzCxNkBpenN? M13Id2Fod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gWGxTPyCneIDy[ZN{\WRiaX6gTGVMKGOnbHzzJIFnfGW{IEigeI8hOTJiaILzJIJ6KE6Ia3HwdIFDN1OHQWCgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3ME2xMlM1|ryPLh?= M{LTNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUWyNFQ3Lz5{OUG1NlA1PjxxYU6=
HEK MkLnSpVv[3Srb36gZZN{[Xl? NXLRR5pLOjRiaILz NIDBRndC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJHRNWjdidILhcpNn\WO2ZXSgbY4hUEWNIHPlcIx{KGG|c3Xzd4VlKGG|IF7Gb4FxeGGEIHnu[JVkfGmxbjDh[pRmeiB{NDDodpMh[nlic4DlZ4lncWNic3XjdoV1\WRiYXzrZYxqdmVicHjvd5Bp[XSjc3Wg[4Vv\SCjc4PhfUwhTUN3ME2xMlTPxE1w NEHEOWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkizO|gyOSd-MkK4N|c5OTF:L3G+
HEK293 MUXGeY5kfGmxbjDhd5NigQ>? MYWyOEBpenN? NYjjb45iSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBVVFJvNzDlfJBz\XO|ZXSgbY4hUEWNMkmzJINmdGy|IHHmeIVzKDJ2IHjyd{BjgSCVRVHQJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUC9NU42|ryPLh?= NG\I[2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO4N|Q4PSd-MkSzPFM1PzV:L3G+
HEK293 MXLGeY5kfGmxbjDhd5NigQ>? M{fVeVYhcHK| NYKwNIFCSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBVVFJ6IHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNiaX7jeYJifGWmIH\vdkA3KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVA:PM7:TT6= NYXBOYF1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkeyO|AxOjlpPkK3NlcxODJ7PD;hQi=>
HEK293 NU\iTXFbTnWwY4Tpc44h[XO|YYm= MV6yOEBpenN? NWrsUoNMSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBVVFJvODDlfJBz\XO|ZXSgbY4hUEWNMkmzJINmdGy|IHHmeIVzKDJ2IHjyd{BjgSCVRVHQJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUC9OE42|ryPLh?= Mn7YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|OEO0O|UoRjJ2M{izOFc2RC:jPh?=
HEK MUDGeY5kfGmxbjDhd5NigQ>? M1:xNVghfG9iMUKgbJJ{ MnTuRYdwdmm|dDDhZ5Rqfmm2eTDheEBpfW2jbjDUUHI5KGW6cILld5Nm\CCrbjDISWsh[2WubIOgZYZ1\XJiODD0c{AyOiCqcoOgZpkhVk[tYYDwZWIwW0WDUDDy[ZBwenSncjDn[Y5mKGG|c3H5MEBGSzVyPU[uNVPPxE1w M1\mZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUWyNFQ3Lz5{OUG1NlA1PjxxYU6=
HEK NGL3dYFHfW6ldHnvckBie3OjeR?= NFj6eoozPCCqcoO= MXXB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIGTMVlghfHKjboPm[YN1\WRiaX6gTGVMKGOnbHzzJIF{e2W|c3XkJIF{KE6Ia3HwdIFDKGmwZIXjeIlwdiCjZoTldkAzPCCqcoOgZpkhe3CnY3nmbYMhe2WlcnX0[YQh[WytYXzpcoUheGixc4DoZZRie2ViZ3Xu[UBie3OjeTygSWM2OD14LkVOwG0v NUSye25LRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4N|c5OTFpPkKyPFM4QDFzPD;hQi=>
PBMC NHPNfWxHfW6ldHnvckBie3OjeR?= M1vEXVI1KGi{cx?= MljYTY5kemWjc3WgbY4hUU[QYXzwbIEhdGW4ZXygbY4hcHWvYX6gVGJOSyCjZoTldkAzPCCqcoOgdoVt[XSrdnWgeI8h[2:wdILvcC=> MmfNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3NEi0PVcoRjF5NUS4OFk4RC:jPh?=
PBMC NGPUZ2JHfW6ldHnvckBie3OjeR?= MkOyNlQhcHK| MkXITY5kemWjc3WgbY4hOiduNTetc4xq\2:jZHXufYxifGVic4nueIhie2VibHX2[YwhcW5iaIXtZY4hWEKPQzDh[pRmeiB{NDDodpMhemWuYYTpeoUhfG9iY3;ueJJwdA>? M1jSNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUS4OFk4Lz5zN{W0PFQ6PzxxYU6=
PBMC NWrxVWtbXG:6aXPpeJkh[XO|YYm= MlHxNlQhcHK| Mk\WWI95cWOrdImgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iSVy2JIxmfmWuIHnuJIh2dWGwIGDCUWMh[W[2ZYKgNlQhcHK|IILlcIF1cX[nIITvJINwdnS{b3y= NUjOR3o1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OFg1QTdpPkG3OVQ5PDl5PD;hQi=>
Huh7 MWXBcpRqfmm{YXygZZN{[Xl? NEiyenMzPCCqcoO= M{P6WmFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhEXiCrbn\lZ5Rm\CCqdX3hckBJfWh5IILldIxq[2:wIHPlcIx{KHS{ZXH0[YQh\m:{IEK0JIhzeyC5aYToJIRzfWdvaX7keYNm\CCqdX3hckBRSk2FIIP1dIVzdmG2YX70d{Bie3Onc4Pl[EBieyC4aYLhcEBt\X[nbIOgZpkhdHWlaX\ldoF{\SCjc4PhfS=> MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV2OES5O{c,OTd3NEi0PVc9N2F-
Huh7 M1fCfGFvfGm4aYLhcEBie3OjeR?= MVHBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDIR3YhcW6oZXP0[YQhcHWvYX6gTJVpPyC{ZYDsbYNwdiClZXzsd{B1emWjdHXkJJdqfGhiZIL1[{1qdmS3Y3XkJIh2dWGwIGDCUWMhe3WyZYLuZZRidnS|IHHzd4V{e2WmIHHzJJZqemGuIHzleoVteyCkeTDseYNq\mW{YYPlJIF{e2G7 M{n5XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUS4OFk4Lz5zN{W0PFQ6PzxxYU6=
PBMC NYLiZYF7TnWwY4Tpc44h[XO|YYm= Mln3NlIvPSC3TR?= MYKyOEBpenN? NUCxSYs3SWexbnnzeEBi[3Srdnn0fUBifCCWTGK3M3RNWjhiaX6gbJVu[W5iUFLNR{Bie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gWG5HNWGucHjhJJBzd2S3Y4Tpc44h[XRiMkKuOUB2VSCjZoTldkAzPCCqcoOgZpkh\myxdzDjfZRwdWW2cnnjJIFv[Wy7c3nz NXLHNmZMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzPFM1PzVpPkK0N|g{PDd3PD;hQi=>
PBMC NEDL[GFKdW23bn;tc4R2dGG2b4L5JIF{e2G7 Mo\uNVYhfU1? NIDsbnMzPCCqcoO= Mn7jTY1ufW6xbX;keYxifG:{eTDhZ5Rqfmm2eTDpckBpfW2jbjDQRm1EKGG|c3Xzd4VlKGG|IHnu[JVkfGmxbjDv[kBKVC14IIPlZ5JmfGmxbjDheEAyPiC3TTDh[pRmeiB{NDDodpMh[nliRVzJV2E> NXHtV405RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyOVQ1QDRpPkK4NlU1PDh2PD;hQi=>
BMD NGnhOYVHfW6ldHnvckBie3OjeR?= NVOxZYpMOSC3TR?= M3nre|Q5KGi{cx?= MmfYTY5lfWO2aX;uJI9nKFSOUkegdoVk\XC2b4KtcYVlcWG2ZXSgR|U4SkxxNjDtc5V{\SCETVSgZ4VtdHNiYXP0bZZifGmxbjDhd5Nme3OnZDDhd{B2eHKnZ4XsZZRqd25ib3[gR2Q5PiCjdDCxJJVOKGGodHXyJFQ5KGi{czDifUBndG:5IHP5eI9u\XS{eR?= NVPvfmF[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmyPVkyOjZpPkG5Nlk6OTJ4PD;hQi=>
BMD MoC2SpVv[3Srb36gZZN{[Xl? NF7JcHAyKHWP M1XzelQ5KGi{cx?= NWfVWW43UW6mdXP0bY9vKG:oIGTMVlchemWlZYD0c5IudWWmaXH0[YQhSzV5QlyvOkBud3W|ZTDCUWQh[2WubIOgZYN1cX[jdHnvckBie3Onc4Pl[EBieyC3cILl[5Vt[XSrb36gc4YhVUiFIHPsZZN{NTJiYYSgNUB2VSCjZoTldkA1QCCqcoOgZpkh\myxdzDjfZRwdWW2com= MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ7OUGyOkc,OTl{OUmxNlY9N2F-
BMD M2jKZmZ2dmO2aX;uJIF{e2G7 MoeyNUB2VQ>? Mlf0OFghcHK| NU\xWVhtUW6mdXP0bY9vKG:oIGTMVlchemWlZYD0c5IudWWmaXH0[YQhSzV5QlyvOkBud3W|ZTDCUWQh[2WubIOgZYN1cX[jdHnvckBie3Onc4Pl[EBieyC3cILl[5Vt[XSrb36gc4YhS0R2MDDheEAyKHWPIHHmeIVzKDR6IHjyd{BjgSCobH;3JIN6fG:vZYTyfS=> NX3YR4RSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmyPVkyOjZpPkG5Nlk6OTJ4PD;hQi=>
BMD MkfoSpVv[3Srb36gZZN{[Xl? M3[0VlUhfU1? NFi5cZozPCCqcoO= NUD6W3lxUW6mdXP0bY9vKG:oIGTMVlchemWlZYD0c5IudWWmaXH0[YQhSzV5QlyvOkBud3W|ZTDCUWQh[2WubIOgZYN1cX[jdHnvckBie3Onc4Pl[EBieyCLTEGyJJBzd2S3Y4Tpc44h[XRiNTD1UUBi\nSncjCyOEBpenNiYomgSWxKW0F? MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ7OUGyOkc,OTl{OUmxNlY9N2F-
In vivo In wild-type mice, Resiquimod (50 nmol, i.p.) induces increased serum concentrations of IFN-alpha, TNF-alpha and IL-12, while neither TLR7-deficient mice nor MyD88-deficient mice show an increase in these cytokines. [1] In a murine model of allergic asthma, Resiquimod (i.n., 20 μg/mouse) reduces allergen induced airway reactivity and inflammation via reduction in Nrf2 signaling. [4]

Protocol (from reference)

Animal Research:

[1]

  • Animal Models: Wild-type mice, TLR7-deficient mice, and MyD88-deficient mice
  • Dosages: 50 nmol
  • Administration: i.p.

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 314.38
Formula

C17H22N4O2

CAS No. 144875-48-9
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCOCC1=NC2=C(N1CC(C)(C)O)C3=CC=CC=C3N=C2N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04127864 Active not recruiting Procedure: Colorectal cancer surgery Colorectal Cancer|Surgery University of Copenhagen|Zealand University Hospital October 14 2019 --
NCT02688478 Unknown status Other: Phthalate|Other: Filtered Air|Other: Allergen Allergies University of British Columbia February 2 2017 Not Applicable
NCT00960752 Completed Drug: gp100|Drug: R848 gel|Drug: MAGE-3 Melanoma M.D. Anderson Cancer Center May 20 2010 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Resiquimod (R-848) | Resiquimod (R-848) supplier | purchase Resiquimod (R-848) | Resiquimod (R-848) cost | Resiquimod (R-848) manufacturer | order Resiquimod (R-848) | Resiquimod (R-848) distributor